


CLAIMS

1. A monoclonal antibody or a fragment thereof which has affinity for compounds represented by formula (II):

5




(II)

Must be prepared
using immunogen (I)
reproducible?

(wherein R^{1a}, R^{3a} and R^{4a}, which may be the same or different, each represents OH or acyloxy¹) and which does not substantially react with compounds represented by formula (A):

10




(A)

12/22/21

15 (wherein R^{1A}, R^{3A} and R^{4A}, which may be the same or
different, each represents OH or acyloxy) or compounds
represented by formula (B):


15



(wherein R^{1B} , R^{2B} and R^{3B} , which may be the same or different, each represents OH or acyloxy), said affinity for the compounds represented by formula (II) decreasing in the order of Compound 1-1 > Compound 1-2 > Compound 1-3, wherein Compound 1-1 is a compound represented by formula (II) in which R^{1a} and R^{3a} are $OCOCH_3$ and R^{4a} is OH, Compound 1-2 is a compound represented by formula (II) in which R^{1a} and R^{4a} are OH and R^{3a} is $OCOCH_3$, and Compound 1-3 is a compound represented by formula (II) in which R^{1a} , R^{3a} and R^{4a} are $OCOCH_3$.

2. The monoclonal antibody or a fragment thereof according to claim 1, wherein the monoclonal antibody is monoclonal antibody KTM-205 produced by hybridoma KTM-205.

3. A monoclonal antibody or a fragment thereof which has affinity for compounds represented by formula (III):




(wherein R^{1b} , R^{3b} and R^{4b} , which may be the same or different, each represents OH or acyloxy; and R^{2b}

10030524 04402

represents H, OH or acyloxy, provided that when R^{2b} is H or OH, at least one of R^{1b} , R^{3b} and R^{4b} is acyloxy) and which does not substantially react with compounds represented by formula (C):

5




(wherein R^{1C} , R^{2C} and R^{3C} , which may be the same or different, each represents OH or acyloxy), said affinity for the compounds represented by formula (III) decreasing in the order of Compound 2-1 > Compound 2-2 > Compound 2-3, wherein Compound 2-1 is a compound represented by formula (III) in which R^{1b} and R^{3b} are $OCOCH_3$, R^{2b} is H and R^{4b} is OH, Compound 2-2 is a compound represented by formula (III) in which R^{1b} , R^{3b} and R^{4b} are $OCOCH_3$ and R^{2b} is H, and Compound 2-3 is a compound represented by formula (III) in which R^{1b} and R^{4b} are OH and R^{2b} and R^{3b} are $OCOCH_3$.

4. The monoclonal antibody or a fragment thereof according to claim 3, wherein the monoclonal antibody is monoclonal antibody KTM-240 produced by hybridoma KTM-240.


5. A monoclonal antibody or a fragment thereof which has affinity for compounds represented by formula (IV):

25

10030624.04402



(wherein R^{1c} , R^{2c} and R^{3c} , which may be the same or different, each represents OH or acyloxy, provided that at least one of R^{1c} , R^{2c} and R^{3c} is acyloxy) and which does not substantially react with compounds represented by formula (D):



10

(wherein R^{1D} , R^{3D} and R^{4D} , which may be the same or different, each represents OH or acyloxy, and R^{2D} is H, OH or acyloxy), said affinity for the compounds represented by formula (IV) decreasing in the order of Compound 3-1 > Compound 3-2, wherein Compound 3-1 is a compound represented by formula (IV) in which R^{1c} is OH and R^{2c} and R^{3c} are OCOCH_3 , and Compound 3-2 is a compound represented by formula (IV) in which R^{1c} , R^{2c} and R^{3c} are OCOCH_3 .

20

6. The monoclonal antibody or a fragment thereof according to claim 5, wherein the monoclonal antibody is monoclonal antibody KTM-249 produced by hybridoma KTM-249.

7. A hybridoma which is capable of producing the

1.0030621.014102

monoclonal antibody according to claim 1 or 2.

8. A hybridoma which is capable of producing the monoclonal antibody according to claim 3 or 4.

5

9. A hybridoma which is capable of producing the monoclonal antibody according to claim 5 or 6.


10. The hybridoma according to claim 7 deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology under accession number FERM BP-6835.

11. The hybridoma according to claim 8 deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology under accession number FERM BP-6836.

12. The hybridoma according to claim 9 deposited with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology under accession number FERM BP-6837.

SubAS 13. A process for producing a hybridoma which produces the monoclonal antibody according to any of claims 1 to 6, which comprises immunizing an animal by administering to the animal a substance prepared from a compound represented by formula (I):

10030624.04403



(wherein R^1 represents H or acyloxy; R^2 , R^3 and R^4 , which may be the same or different, each represents H, OH or acyloxy; and Z^1 represents $\text{OCOCH}_2\text{CH}(\text{CH}_3)_2$ and Z^2 represents H, or Z^1 and Z^2 together represent $=\text{O}$, provided that at least one of R^1 , R^2 , R^3 and R^4 is OH) by converting at least one of the hydroxyl groups therein to acyloxy and binding a carrier substance to the carbon at the 3-position thereof, and fusing an antibody-producing cell obtained from the immunized animal with a permanent growth cell to obtain the hybridoma.

14. The process according to claim 13, wherein R^2 in formula (I) is acyloxy.

15. The process according to claim 13, wherein the binding of the carrier substance to the carbon at the 3-position of a compound prepared from the compound represented by formula (I) by converting at least one of the hydroxyl groups therein to acyloxy is carried out by using a substituent at the 3-position as a linker.

16. The process according to claim 13, wherein a compound prepared from the compound represented by formula (I) by converting at least one of the hydroxyl groups therein to a group represented by OR (wherein R represents a substituted or unsubstituted lower acyl group or a

10030624.01102

substituted or unsubstituted aromatic acyl group) is dissolved in a solvent which is not an organic solvent or which does not contain an organic solvent and then conjugated to the carrier substance.

5

17. The process according to claim 16, wherein the solvent which is not an organic solvent or which does not contain an organic solvent is water.

10

18. An immunoassay for determining a trichothecene mycotoxin in a sample, which comprises causing at least one of the monoclonal antibodies and fragments thereof according to claims 1 to 6 to act on the sample containing the trichothecene mycotoxin.

15

19. An immunoassay for determining a trichothecene mycotoxin in a sample, which comprises converting at least one hydroxyl group in a compound represented by formula (I) having at least one hydroxyl group to a group represented by OR (wherein R represents a substituted or unsubstituted lower acyl group or a substituted or unsubstituted aromatic acyl group), and causing at least one of the monoclonal antibodies and fragments thereof according to claims 1 to 6 to act on the obtained compound.

25

Sub A6

20. The immunoassay according to claim 18 or 19, wherein the trichothecene mycotoxin is selected from the group consisting of deoxynivalenol (DON), nivalenol (NIV), T-2 toxin (T-2) and derivatives thereof.

30

21. A method for determining the total amount of DON, NIV, T-2 and derivatives thereof in a sample, which comprises calculating the total amount from the value obtained by the immunoassay according to claim 18 or 19 using the monoclonal antibody or a fragment thereof according to claim 3 or 4 and the value obtained by the

35

10030621.011102
meth. steps

Sub A 6 2008 immunoassay according to claim 18 or 19 using the monoclonal antibody or a fragment thereof according to claim 5 or 6.

5 22. A method for determining NIV and its derivatives in a sample, which comprises carrying out the immunoassay according to claim 18 or 19 using the monoclonal antibody or a fragment thereof according to claim 1 or 2.

10 23. A method for determining DON, NIV and derivatives thereof in a sample, which comprises carrying out the immunoassay according to claim 18 or 19 using the monoclonal antibody or a fragment thereof according to claim 3 or 4.

15 24. A method for determining DON and its derivatives in a sample, which comprises calculating the amount of DON and its derivatives from the value obtained by the immunoassay according to claim 18 or 19 using the monoclonal antibody or a fragment thereof according to claim 3 or 4 and the value obtained by the immunoassay according to claim 18 or 19 using the monoclonal antibody or a fragment thereof according to claim 1 or 2.

25 25. A method for determining T-2 and its derivatives in a sample, which comprises carrying out the immunoassay according to claim 18 or 19 using the monoclonal antibody or a fragment thereof according to claim 5 or 6.

30 26. The immunoassay according to claim 18 or 19, wherein the immunoassay is selected from the group consisting of radioimmunoassay, enzyme immunoassay, fluoroimmunoassay and luminescence immunoassay.

35 27. The immunoassay according to claim 18 or 19, wherein the immunoassay is selected from the group

10030621.01102

consisting of competitive immunoassay and sandwich immunoassay.

28. A reagent for immunoassay for determining a
5 trichothecene mycotoxin, comprising at least one of the
monoclonal antibodies and fragments thereof according to
claims 1 to 6 as an active ingredient.

29. A kit for immunoassay for determining a
10 trichothecene mycotoxin, comprising the reagent according
to claim 28 and an antigen-immobilized solid phase plate.

SubA7 30. A kit for immunoassay for determining a
trichothecene mycotoxin, comprising the reagent according
15 to claim 28, an antigen-immobilized solid phase plate, a
labeled antibody or antibody fragment which reacts with
the monoclonal antibody or a fragment thereof according to
any of claims 1 to 6, and a reagent for detecting the
label of said antibody or antibody fragment.

20
31. A kit for immunoassay for determining a
trichothecene mycotoxin, comprising an antigen-immobilized
solid phase plate, the monoclonal antibody or a fragment
thereof according to any of claims 1 to 6 which is labeled,
25 and a reagent for detecting the label of said antibody or
antibody fragment.

32. A kit for immunoassay for determining a
trichothecene mycotoxin, comprising the reagent according
30 to claim 28 and a solution for the pretreatment of a
sample to convert a hydroxyl group in a compound
represented by formula (I) to a group represented by OR
(wherein R has the same significance as defined above).

35 33. A kit for immunoassay for determining a
trichothecene mycotoxin, comprising the reagent according

10030621.01.102

to claim 28, an antigen-immobilized solid phase plate, and a solution for the pretreatment of a sample to convert a hydroxyl group in a compound represented by formula (I) to a group represented by OR (wherein R has the same
5 significance as defined above).

Sub A8 34. A kit for immunoassay for determining a trichothecene mycotoxin, comprising the reagent according to claim 28, an antigen-immobilized solid phase plate, a
10 labeled antibody or antibody fragment which reacts with the monoclonal antibody or a fragment thereof according to any of claims 1 to 6, a reagent for detecting the label of said antibody or antibody fragment, and a solution for the pretreatment of a sample to convert a hydroxyl group in a
15 compound represented by formula (I) to a group represented by OR (wherein R has the same significance as defined above).

35. A kit for immunoassay for determining a
20 trichothecene mycotoxin, comprising an antigen-immobilized solid phase plate, the monoclonal antibody or a fragment thereof according to any of claims 1 to 6 which is labeled, a reagent for detecting the label of said antibody or antibody fragment, and a solution for the pretreatment of
25 a sample to convert a hydroxyl group in a compound represented by formula (I) to a group represented by OR (wherein R has the same significance as defined above).

Sub A9 36. A method for determining a trichothecene
30 mycotoxin in a sample, which comprises treating the sample containing the trichothecene mycotoxin with a solution containing an organic solvent to extract the trichothecene mycotoxin from the sample, and determining the extracted trichothecene mycotoxin by the immunoassay according to
35 claim 18 or 19.

10030621.011102

37. The method according to claim 36, wherein the organic solvent is a water-soluble organic solvent.

~~Sub A 10~~ 38. The method according to claim 36 or 37, wherein the water-soluble organic solvent is at least one member selected from the group consisting of methyl alcohol, ethyl alcohol, propyl alcohol, acetonitrile, dimethyl sulfoxide and dimethylformamide.

10 39. A method for detecting a microorganism producing a trichothecene mycotoxin in a sample by immunoassay, which comprises inoculating the sample containing the microorganism producing the trichothecene mycotoxin into a medium, culturing the microorganism in the medium, and
15 causing at least one of the monoclonal antibodies and fragments thereof according to claims 1 to 6 to act on the trichothecene mycotoxin produced in the culture.

20 40. A method for identifying a microorganism producing a trichothecene mycotoxin in a sample by immunoassay, which comprises inoculating the sample containing the microorganism producing the trichothecene mycotoxin into a medium, culturing the microorganism in the medium, and causing at least one of the monoclonal
25 antibodies and fragments thereof according to claims 1 to 6 to act on the trichothecene mycotoxin produced in the culture.

ADD AM

10030621 011102